Composition for preventing or alleviating skin inflammation caused by fine dust, comprising astilboides tabularis (hemsl.) engl. extract as active ingredient
*Clematis terniflora* extract addresses skin inflammation and moisture retention issues by inhibiting inflammatory markers and enhancing skin barrier function, offering a natural and effective solution for fine dust-induced skin irritation.
Patent Information
- Application Number
- PCT/KR2026/004601
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-03-23
- Publication Date
- 2026-11-19
AI Technical Summary
Existing natural ingredients like afzelin and black yeast extract are insufficient in addressing skin inflammation and moisture retention issues caused by fine dust, and there is a lack of research on Astilboides tabularis extracts for fine dust-induced skin irritation.
A composition containing *Clematis terniflora* extract, specifically its ethyl acetate fraction, is used to inhibit the expression of inflammatory markers COX-2, iNOS, TNF-α, and IFN-β, while enhancing skin barrier function and moisture retention by increasing the expression of filaggrin, AQP-3, HAS-1, and HAS-2.
The *Clematis terniflora* extract effectively reduces inflammatory markers and improves skin barrier function and moisture retention, demonstrating low skin irritation potential and significant inhibitory effects on inflammatory signaling factors.
Smart Images

Figure KR2026004601_19112026_PF_FP_ABST
Abstract
Description
A composition for preventing or improving skin inflammation caused by fine dust, containing *Clematis terniflora* extract as an active ingredient.
[0001] The present invention relates to a composition for preventing or improving skin inflammation caused by fine dust, comprising an extract of *Clematis terniflora* as an active ingredient.
[0002] With the rapid increase in atmospheric fine dust concentrations due to modern urbanization and industrialization, the risk of causing skin diseases is emerging as a social issue. Fine dust causes chronic skin inflammation, such as atopic dermatitis, acne, and eczema, through pathological mechanisms including penetration into the epidermal layer of the skin, inducing oxidative stress, damaging skin barrier function, and promoting the secretion of inflammatory cytokines.
[0003] Fine dust consists of particles suspended in the air, classified into PM-10 and PM-2.5 based on their size. PM-10 consists of particles with an average diameter of less than 10 μm, primarily generated from natural or industrial activities such as road dust; while they irritate the nose and throat, they do not penetrate deep into the lungs. On the other hand, PM-2.5 consists of particles with an average diameter of less than 2.5 μm, produced by sources such as automobile exhaust and the combustion of fossil fuels; they can penetrate the alveoli or enter the bloodstream, potentially causing cardiovascular and respiratory diseases.
[0004] Heavy metals (Cd, Pb) and polycyclic aromatic hydrocarbons (PAHs) in fine dust penetrate the epidermal layer of the skin and induce NADPH oxidase activation. The reactive oxygen species (ROS) generated as a result promote lipid peroxidation reactions in cell membranes, leading to mitochondrial dysfunction and DNA damage. In the case of PM-10, it penetrates the epidermal layer to generate reactive oxygen species and activates the p38 MAPK / NF-κB signaling pathway, causing the overexpression of inflammatory cytokines such as COX-2, iNOS, and TNF-α. During this process, the expression of skin barrier proteins such as filaggrin and loricrin is suppressed, resulting in defects in the stratum corneum and an increase in transepidermal water loss (TEWL). In particular, it has been experimentally proven that exposure to fine dust impairs skin barrier function mediated by TNF-α through the aryl hydrocarbon receptor (AhR) pathway.
[0005] Astilboides tabularis (Hemsl.) Engl. is a perennial herb belonging to the Saxifragaceae family that has traditionally been used for blood sugar control. The plant has large leaves and a unique appearance resembling an unfolded folding screen, which is the origin of its name. Recent research on Astilboides tabularis extracts has demonstrated an IL-17 / CCL2 axis inhibitory effect in a UVB-induced solar dermatitis model; however, there have been no studies regarding its various therapeutic effects on skin irritated by fine dust.
[0006] Natural ingredients such as afzelin and black yeast (Aureobasidium pullulans) extract are existing anti-inflammatory substances effective against oxidative stress. Although the aforementioned afzelin was confirmed to have a selective inhibitory effect on the inflammatory mediator (IL-1α) in HaCaT cells exposed to fine dust, its effect on improving the expression of skin moisturization-related markers (filagrin, HAS-2, etc.) was insufficient. While black yeast extract has been verified for its UV blocking and antibacterial effects, there is a lack of research on fine dust-induced oxidative stress. The antioxidants resveratrol and EGCG improve skin dryness caused by PM-10, but safety issues have been raised due to concentration-dependent differences in efficacy.
[0007] Against this backdrop, the present invention aims to overcome these limitations by confirming the anti-inflammatory activity of *Clematis terniflora* extract and verifying multiple biological activities.
[0008] [Prior Art Literature]
[0009] [Patent Literature]
[0010] Korean Registered Patent No. 10-1817109
[0011] The present invention aims to obtain an extract from *Clematis terniflora* and to provide a composition for preventing or improving skin inflammation caused by fine dust by including the *Clematis terniflora* extract as an active ingredient.
[0012] To solve the above problem, the present invention provides a composition for preventing or improving skin inflammation caused by fine dust, comprising an extract of *Clematis terniflora* as an active ingredient.
[0013] The composition containing the extract of *Clematis terniflora* according to the present invention effectively reduces the expression of COX-2, iNOS, TNF-α, and IFN-β in skin tissues induced by fine dust, thereby acting on multiple inflammatory targets. Furthermore, the *Clematis terniflora* extract has the effect of simultaneously improving skin barrier strengthening and moisture retention capabilities, so the composition containing it is effective in improving skin barrier function.
[0014] Figures 1a and 1b show the inhibitory effect of *Clematis terniflora* extract on the cytotoxicity of artificial skin tissues Neoderm-ED and Neoderm-ME. Each data point is expressed as the mean ± standard deviation of three replicate experiments. Superscript ( * p<0.05, ** p<0.01, *** A significant difference between the control group and the experimental group was indicated through an independent samples t-test (p<0.001). The above-mentioned *Clematis terniflora* extract was extracted from the *Clematis terniflora* root, and when 75 μg / mL of the *Clematis terniflora* root ethyl acetate fraction was treated as the *Clematis terniflora* extract, the cell viability (%) of Neoderm-ED was 79.7% (Fig. 1a) and the cell viability of Neoderm-ME was 77.4% (Fig. 1b), indicating that the *Clematis terniflora* root ethyl acetate fraction as the *Clematis terniflora* extract has a low potential for skin irritation and high suitability for skin application.
[0015] Figures 2a to 2d show the results of confirming the expression levels of inflammatory signaling factors COX-2, iNOS, TNF-α, and IFN-β in skin cells stimulated by fine dust to confirm the anti-inflammatory effect of the *Clematis terniflora* extract. The anti-inflammatory effect of the *Clematis terniflora* extract was confirmed using the ethyl acetate fraction of the *Clematis terniflora* root.
[0016] Figures 3a to 3d show the results of confirming the moisturizing and skin barrier strengthening effects of *Clematis terniflora* extract in skin cells stimulated by fine dust by examining the expression levels of markers related to moisturizing and skin barrier strengthening, such as filaggrin, AQP-3, HAS-1, and HAS-2.
[0017] Figure 4 shows the results of histological analysis to evaluate the restorative effect of the ethyl acetate fraction of the *Scutellaria baicalensis* root extract on fine dust-induced skin damage using a Neoderm-ED artificial skin model composed of the epidermis and dermis. H&E stained images of the 3D cultured skin were acquired at a magnification of 1,000x. Figure 4(A): Untreated with fine dust; Figure 4(B): Stimulated with fine dust; Figure 4(C): Artificial skin tissue stimulated by fine dust treated with 10 μg / mL of *Scutellaria baicalensis* extract; Figure 4(D): Artificial skin tissue stimulated by fine dust treated with 25 μg / mL of *Scutellaria baicalensis* extract; Figure 4(E): Artificial skin tissue stimulated by fine dust treated with 50 μg / mL of *Scutellaria baicalensis* extract; Figure 4(F): Artificial skin tissue stimulated by fine dust treated with 75 μg / mL of *Scutellaria baicalensis* extract. Each data point was obtained from three replicate experiments.
[0018] Hereinafter, various embodiments of the present invention are described with reference to the accompanying drawings. The present invention is not limited to specific embodiments and should be understood to include various modifications, equivalents, and / or alternatives of the embodiments of the present invention. In relation to the description of the drawings, similar reference numerals may be used for similar components.
[0019] In this document, expressions such as "have," "can have," "include," or "can include" refer to the existence of the relevant feature (e.g., numerical values, functions, actions, or components, etc.) and do not exclude the existence of additional features.
[0020] In this document, expressions such as “A or B,” “at least one of A or / and B,” or “one or more of A or / and B” may include all possible combinations of items listed together. For example, “A or B,” “at least one of A and B,” or “at least one of A or B” may refer to cases including (1) at least one A, (2) at least one B, or (3) both at least one A and at least one B.
[0021] As used in this document, the expression "configured to" may be replaced, depending on the context, with, for example, "suitable for," "having the capacity to," "designed to," "adapted to," "made to," or "capable of." The term "configured to" does not necessarily mean "specifically designed to."
[0022] The terms used in this document are used merely to describe specific embodiments and are not intended to limit the scope of other embodiments. Singular expressions may include plural expressions unless the context clearly indicates otherwise. Terms used herein, including technical or scientific terms, may have the same meaning as generally understood by those skilled in the art described in this document. Terms used in this document that are defined in general dictionaries may be interpreted as having the same or similar meaning as they have in the context of the relevant technology, and are not to be interpreted in an ideal or overly formal sense unless explicitly defined in this document. In some cases, even terms defined in this document may not be interpreted to exclude the embodiments of this document.
[0023] The embodiments disclosed in this document are presented for the purpose of explaining and understanding the disclosed technical content and are not intended to limit the scope of the invention. Accordingly, the scope of this document should be interpreted to include all modifications or various other embodiments based on the technical concept of the invention.
[0024] Hereinafter, preferred embodiments of the present invention will be described in detail. Prior to this, terms and words used in this specification and claims should not be interpreted as being limited to their ordinary or dictionary meanings, and should be interpreted in a meaning and concept consistent with the technical spirit of the present invention, based on the principle that the inventor can appropriately define the concept of the terms to best describe his invention.
[0025] Therefore, it should be understood that the configurations of the embodiments described in this specification are merely some of the most preferred embodiments of the present invention and do not represent all of the technical ideas of the present invention, and that various equivalents and modifications that can replace them may exist at the time of filing this application.
[0026] Throughout the specification, when a part is described as "including" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.
[0027] The present invention will be described in detail below.
[0028]
[0029] According to one embodiment of the present invention, a composition for preventing or improving skin inflammation caused by fine dust is provided, comprising an extract of *Clematis terniflora* as an active ingredient. Each component is described in detail below.
[0030] The above-mentioned Saxifragaceae is a perennial herbaceous plant belonging to the family Saxifragaceae, characterized by a thick rhizome structure, roots rich in polysaccharides and phenolic compounds, and shield-shaped leaves reaching 60 to 90 cm in diameter. In the summer, white flowers bloom in the form of racemes on flower stalks 1 to 1.5 m long.
[0031] The above-mentioned *Clematis terniflora* extract may be a *Clematis terniflora* root extract.
[0032] The above-mentioned *Clematis terniflora* extract may be a *Clematis terniflora* root ethyl acetate fraction obtained by reflux extracting *Clematis terniflora* roots with 70% ethanol (EtOH), diluting the *Clematis terniflora* root extract with distilled water, and then sequentially fractionating it with n-hexane, ethyl acetate, water-saturated butanol, and an aqueous solution.
[0033] The above fraction refers to a group of substances further purified from an extract based on specific physical and chemical properties (polarity, molecular weight, solubility, etc.). It is obtained by separating the extract using methods such as solvent partitioning, column chromatography, or crystallization, and is characterized by a concentration of the target physiologically active component. In the present invention, the *Scutellaria baicalensis* root fraction refers to a *Scutellaria baicalensis* root extract purified by sequential solvent partitioning using n-hexane, ethyl acetate, water-saturated butanol, and an aqueous solution. Preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root extract. More preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root fraction obtained by the sequential solvent partitioning method. Even more preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root ethyl acetate fraction.
[0034] The above-mentioned root fraction of *Clematis terniflora* may be characterized by removing lipid impurities with n-hexane, concentrating intermediate polar flavonoids (catechin, quercetin) with ethyl acetate, extracting high polar glycosides using water-saturated butanol, and containing polymers and polysaccharides remaining in the aqueous layer.
[0035] When the above-mentioned Adenophora root is reflux-extracted with 70% ethanol (EtOH), the Adenophora root extract may contain flavonoids such as catechin, quercetin, and isoquercitrin as main components. When this extract is diluted with distilled water and then sequentially fractionated with n-hexane, ethyl acetate, water-saturated butanol, and an aqueous solution, the flavonoid components, which are anti-inflammatory active ingredients, can be concentrated by more than 65% in the Adenophora root ethyl acetate fraction, which is the ethyl acetate layer. A composition containing the above-mentioned Adenophora root ethyl acetate fraction has the effect of increasing the COX-2 inhibition rate by 3.2 times and the iNOS inhibition rate by 3.1 times compared to the untreated Adenophora root fraction. In addition, the inhibition rates of COX-2 and iNOS were also increased in a skin inflammation model induced by fine dust (see Figs. 2a and 2b). Furthermore, the composition containing the ethyl acetate fraction of the above-mentioned Adenophora root has the effect of reducing TNF-α expression and inhibiting IFN-β secretion in a skin inflammation model induced by fine dust (see FIG. 2c and FIG. 2d).
[0036] The aforementioned fine dust can be classified into PM-10 and PM-2.5 based on particle size. Fine dust can penetrate the epidermal layer of the skin and reach the dermis, and the heavy metal components of fine dust act as chemical irritants to the human body, specifically inducing the generation of reactive oxygen species (ROS) in the skin. These ROS cause skin inflammation and promote the secretion of inflammatory signaling factors such as COX-2, iNOS, TNF-α, or IFN-β. Furthermore, fine dust can impair skin moisturization function by reducing the expression of filaggrin, AQP-3, HAS-1, or HAS-2.
[0037] In the above composition for preventing or improving skin inflammation caused by fine dust, the fine dust may be treated to skin tissue at a concentration of 10 to 75 μg / mL to induce inflammation of the skin tissue. Preferably, the fine dust may be treated to skin tissue at a concentration of 75 μg / mL to induce inflammation of the skin tissue.
[0038] The above "improvement" refers to the action of blocking or reducing the progression of physiological reactions that have already occurred, as well as alleviating symptoms and restoring function. In the present invention, the improvement of skin inflammation includes a mechanism that inhibits the activity of COX-2 and iNOS enzymes or reduces the secretion of inflammatory cytokines such as TNF-α and IFN-β.
[0039] The above "for preventing or improving skin inflammation" refers to a function that encompasses both the pre- and post-stages of inflammation, and implies that it can simultaneously achieve preventive and improvement effects. In the present invention, a composition for preventing or improving skin inflammation caused by fine dust, comprising an extract of *Clematis terniflora* as an active ingredient, wherein the active ingredient has the effect of preventing skin inflammation and inhibiting COX-2 and iNOS enzyme activity, while the catechin and quercetin of the *Clematis terniflora* extract neutralize fine dust-induced reactive oxygen species, thereby inhibiting the secretion promotion of TNF-α, IFN-β, etc., 3.2 times faster, and thus having the effect of improving skin inflammation.
[0040] The above-mentioned Adenophora extract can inhibit the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue irritated by fine dust. Preferably, the above-mentioned Adenophora extract may be an Adenophora root extract. More preferably, the above-mentioned Adenophora extract may be an Adenophora root fraction obtained by sequential solvent fractionation. Even more preferably, the above-mentioned Adenophora extract may be an Adenophora root ethyl acetate fraction.
[0041] The above COX-2 (Cyclooxygenase-2) is an enzyme induced during inflammatory responses, which promotes the expression of inflammatory mediators such as TLR2 / CD14 receptors, thereby causing a continuous vicious cycle of inflammation. In the present invention, the extract of Arachidonic acid inhibits COX-2 expression by more than 30% in skin tissues irritated by fine dust, thereby converting arachidonic acid into prostaglandin E2.
[0042] The above-mentioned iNOS (Inducible Nitric Oxide Synthase) is activated in macrophages and keratinocytes during inflammation and can induce tissue damage and differentiation of M1-type macrophages by overproducing nitric oxide (NO). This nitric oxide inhibits IL-12 secretion, thereby weakening the Th1 immune response, and maintains chronic inflammation by regulating Th17 cell differentiation through RORγt nitration. In the present invention, the extract of Adenophora triphylla can reduce iNOS expression by more than 25% in skin tissues irritated by fine dust, thereby inhibiting nitric oxide production and promoting differentiation of M2-type macrophages (anti-inflammatory type).
[0043] The above TNF-α is a major inflammatory cytokine secreted by macrophages and T cells, which activates the NF-κB pathway and induces the secretion of secondary inflammatory mediators such as IL-6 and IL-8. In the present invention, the extract of *Clematis terniflora* has the effect of alleviating skin irritation by preventing skin barrier damage and neutrophil infiltration by inhibiting TNF-α expression by more than 20% in skin tissues irritated by fine dust.
[0044] The above-mentioned IFN-β is a factor that promotes chemokine secretion and induces an excessive inflammatory response, and upon exposure to fine dust, it increases the expression of pro-inflammatory genes (ICAM-1, VCAM-1) through the formation of the ISGF3 (STAT1 / STAT2 / IRF9) complex. In the present invention, the extract of *Clematis terniflora* can selectively inhibit (reduce by more than 40%) the STAT1-dependent pro-inflammatory pathway of IFN-β, while maintaining IL-10 secretion through the STAT3 pathway, thereby restoring the inflammatory-anti-inflammatory balance.
[0045] The above composition may contain a *Clematis terniflora* extract at a concentration of 5 to 80 μg / mL. Specifically, the above composition may contain a *Clematis terniflora* root extract at a concentration of 10 to 75 μg / mL.
[0046] The above composition may contain a root extract of *Clematis terniflora* at a concentration of 5 to 80 μg / mL. Specifically, the above composition may contain a root extract of *Clematis terniflora* at a concentration of 10 to 75 μg / mL.
[0047] The above composition may contain an ethyl acetate fraction of the root of *Clematis terniflora* at a concentration of 5 to 80 μg / mL. Specifically, the above composition may contain an ethyl acetate fraction of the root of *Clematis terniflora* at a concentration of 10 to 75 μg / mL.
[0048] The above-mentioned *Clematis terniflora* extract can inhibit the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue stimulated by fine dust, and the above-mentioned *Clematis terniflora* extract can reduce the expression of COX-2 in skin tissue stimulated by fine dust by 11% or more. Compared to the COX-2 expression in skin tissue stimulated by fine dust, the COX-2 expression in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 10 μg / mL can be reduced by 11%. Compared to the COX-2 expression in skin tissue stimulated by fine dust, the COX-2 expression in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 25 μg / mL can be reduced by 22%. Compared to the COX-2 expression in skin tissue stimulated by fine dust, the COX-2 expression in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 50 μg / mL can be reduced by 50%. Compared to the COX-2 expression level in skin tissue stimulated by the fine dust mentioned above, the COX-2 expression level in skin tissue treated with the above-mentioned Adenophora extract at a concentration of 75 μg / mL can be reduced by 67%. Preferably, the above-mentioned Adenophora extract may be an Adenophora root extract, and more preferably, the above-mentioned Adenophora extract may be an Adenophora root ethyl acetate fraction.
[0049] The above-mentioned *Clematis terniflora* extract can inhibit the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue stimulated by fine dust, and the above-mentioned *Clematis terniflora* extract can reduce the expression of iNOS in skin tissue stimulated by fine dust by 12% or more. Compared to the expression of iNOS in skin tissue stimulated by fine dust, the expression of iNOS in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 10 μg / mL can be reduced by 12%. Compared to the expression of iNOS in skin tissue stimulated by fine dust, the expression of iNOS in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 25 μg / mL can be reduced by 27%. Compared to the expression of iNOS in skin tissue stimulated by fine dust, the expression of iNOS in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 50 μg / mL can be reduced by 34%. Compared to the expression level of iNOS in skin tissue stimulated by the fine dust mentioned above, the expression level of iNOS in skin tissue treated with the above-mentioned Adenophora extract at a concentration of 75 μg / mL can be reduced by 56%. Preferably, the above-mentioned Adenophora extract may be an Adenophora root extract, and more preferably, the above-mentioned Adenophora extract may be an Adenophora root ethyl acetate fraction.
[0050] The above-mentioned *Clematis terniflora* extract can inhibit the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue stimulated by fine dust, and the above-mentioned *Clematis terniflora* extract can reduce the expression of TNF-α in skin tissue stimulated by fine dust by 29% or more. Compared to the expression of TNF-α in skin tissue stimulated by fine dust, the expression of TNF-α in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 10 μg / mL can be reduced by 29%. Compared to the expression of TNF-α in skin tissue stimulated by fine dust, the expression of TNF-α in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 25 μg / mL can be reduced by 33%. Compared to the expression level of TNF-α in skin tissue stimulated by the fine dust, the expression level of TNF-α in skin tissue treated with the above-mentioned *Calendula* extract at a concentration of 50 μg / mL may be reduced by 50%. Compared to the expression level of TNF-α in skin tissue stimulated by the above-mentioned fine dust, the expression level of TNF-α in skin tissue treated with the above-mentioned *Calendula* extract at a concentration of 75 μg / mL may be reduced by 75%. Preferably, the above-mentioned *Calendula* extract may be a *Calendula* root extract, and more preferably, the above-mentioned *Calendula* extract may be an ethyl acetate fraction of the *Calendula* root.
[0051] The above-mentioned *Clematis terniflora* extract can inhibit the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue stimulated by fine dust, and the above-mentioned *Clematis terniflora* extract can reduce the expression of IFN-β in skin tissue stimulated by fine dust by 12% or more. Compared to the expression of IFN-β in skin tissue stimulated by fine dust, the expression of IFN-β in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 10 μg / mL can be reduced by 12%. Compared to the expression of IFN-β in skin tissue stimulated by fine dust, the expression of IFN-β in skin tissue treated with the above-mentioned *Clematis terniflora* extract at a concentration of 25 μg / mL can be reduced by 34%. Compared to the expression level of IFN-β in skin tissue stimulated by the fine dust, the expression level of IFN-β in skin tissue treated with the above-mentioned *Calendula* extract at a concentration of 50 μg / mL may be reduced by 38%. Compared to the expression level of IFN-β in skin tissue stimulated by the above-mentioned fine dust, the expression level of IFN-β in skin tissue treated with the above-mentioned *Calendula* extract at a concentration of 75 μg / mL may be reduced by 48%. Preferably, the above-mentioned *Calendula* extract may be a *Calendula* root extract, and more preferably, the above-mentioned *Calendula* extract may be an ethyl acetate fraction of the *Calendula* root.
[0052] The above composition for preventing or improving skin inflammation caused by fine dust may contain a *Scutellaria baicalensis* extract at a concentration of 10 μg / mL, and the *Scutellaria baicalensis* extract may be characterized by reducing the expression level of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β by 10% or more. Preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root extract, and more preferably, the *Scutellaria baicalensis* extract may be an ethyl acetate fraction of the *Scutellaria baicalensis* root.
[0053] The above composition for preventing or improving skin inflammation caused by fine dust may contain a *Scutellaria baicalensis* extract at a concentration of 25 μg / mL, and the *Scutellaria baicalensis* extract may be characterized by reducing the expression level of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β by 20% or more. Preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root extract, and more preferably, the *Scutellaria baicalensis* extract may be an ethyl acetate fraction of the *Scutellaria baicalensis* root.
[0054] The above composition for preventing or improving skin inflammation caused by fine dust may contain a *Scutellaria baicalensis* extract at a concentration of 50 μg / mL, and the *Scutellaria baicalensis* extract may be characterized by reducing the expression level of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β by 30% or more. Preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root extract, and more preferably, the *Scutellaria baicalensis* extract may be an ethyl acetate fraction of the *Scutellaria baicalensis* root.
[0055] The above composition for preventing or improving skin inflammation caused by fine dust may contain a *Scutellaria baicalensis* extract at a concentration of 75 μg / mL, and the *Scutellaria baicalensis* extract may be characterized by reducing the expression level of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β by 40% or more. Preferably, the *Scutellaria baicalensis* extract may be a *Scutellaria baicalensis* root extract, and more preferably, the *Scutellaria baicalensis* extract may be an ethyl acetate fraction of the *Scutellaria baicalensis* root.
[0056] The above-mentioned *Clematis terniflora* extract may be characterized by increasing the expression of one or more selected from the group consisting of filaggrin, AQP-3, HAS-1, and HAS-2 in skin tissue stimulated by fine dust.
[0057] In skin tissue stimulated by fine dust, the expression level of one or more selected from the group consisting of filaggrin, AQP-3, HAS-1, and HAS-2 may be reduced. After stimulation by fine dust, the expression level of one or more skin moisturizing markers selected from the group consisting of filaggrin, AQP-3, HAS-1, and HAS-2 in skin tissue may be reduced by more than 30% compared to the expression level in skin tissue before stimulation (see Figs. 3a to 3d). In this case, treatment with *Clematis terniflora* extract in skin tissue stimulated by fine dust may induce a mechanism that inhibits the expression of inflammatory signaling factors (COX-2, iNOS, TNF-α, or IFN-β) and restores the expression of skin moisturizing markers such as filaggrin, AQP-3, HAS-1, and HAS-2. Preferably, the above-mentioned *Clematis terniflora* extract may be a *Clematis terniflora* root extract, and more preferably, the above-mentioned *Clematis terniflora* extract may be an ethyl acetate fraction of the *Clematis terniflora* root.
[0058] The above-mentioned *Clematis terniflora* extract can inhibit TNF-α expression, increase filaggrin gene expression by more than 1.5 times, and promote the production of filaggrin in skin tissues irritated by fine dust. As a result, it has the effect of restoring the moisture retention capacity of the stratum corneum and reversing the decrease in filaggrin caused by fine dust. Therefore, the *Clematis terniflora* extract can have the effect of preventing and inhibiting skin inflammation in skin tissues irritated by fine dust, and strengthening the skin barrier.
[0059] The above-mentioned Adenophora extract can inhibit COX-2 or iNOS expression and restore AQP-3 expression by more than 1.3 times in skin tissues irritated by fine dust. Through this, the efficiency of water circulation between the epidermis and dermis is improved, so the Adenophora extract can have the effect of preventing and improving skin inflammation in skin tissues irritated by fine dust, as well as strengthening the skin barrier by maintaining skin moisture. Preferably, the above-mentioned Adenophora extract may be an Adenophora root extract, and more preferably, the above-mentioned Adenophora extract may be an ethyl acetate fraction of the Adenophora root.
[0060] The above-mentioned Aristolochia extract can inhibit IFN-β and promote the expression of HAS-1 and HAS-2 in skin tissues irritated by fine dust. The above-mentioned IFN-β can inhibit the expression of HAS-1 and HAS-2, which are hyaluronic acid synthesizing enzymes, by more than 35% by inducing gene promoter methylation through the STAT1 pathway. The above-mentioned Aristolochia extract inhibits IFN-β expression in skin tissues irritated by fine dust and promotes hyaluronic acid production by increasing the expression of HAS-1 and HAS-2 by more than 1.4 times, thereby having the effect of preventing and improving skin inflammation in skin tissues irritated by fine dust, as well as strengthening the elasticity and moisturizing capacity of the dermal layer of the skin. Preferably, the above-mentioned Aristolochia extract may be an Aristolochia root extract, and more preferably, the above-mentioned Aristolochia extract may be an ethyl acetate fraction of the Aristolochia root.
[0061] According to another embodiment of the invention, a cosmetic composition for preventing or improving skin inflammation comprising the above composition is provided.
[0062] The above cosmetic composition may contain 0.001 to 10 weight% of *Clematis terniflora* extract as an active ingredient.
[0063] The above cosmetic composition may contain 0.001 to 10 weight% of a root extract of *Clematis terniflora* as an active ingredient.
[0064] The above cosmetic composition may contain 0.001 to 10 weight% of an ethyl acetate fraction of the root of *Clematis terniflora* as an active ingredient.
[0065] The above cosmetic composition may further include water, a surfactant, a moisturizer, or an oil component.
[0066] The cosmetic composition of the present invention may further comprise any conventional cosmetic ingredient selected from additional ingredients commonly used in cosmetics, such as thickeners, dispersants, fragrances, fillers, preservatives, antiseptics, neutralizing agents, sweeteners, vitamins, free-radical scavengers, metal ion chelating agents, functional ingredients, and mixtures thereof. A person skilled in the art may select any additional ingredient and / or the amount thereof so that the advantageous properties of the composition according to this specification are not adversely affected or are substantially affected by the expected addition.
[0067] The cosmetic composition of the present invention may be a cosmetic raw material composition that can be used in the manufacture of cosmetics. In addition, the cosmetic composition may be a cosmetic composition having a final cosmetic formulation.
[0068]
[0069] The present invention will be described in more detail below through examples. These examples are intended solely to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention.
[0070]
[0071] Examples
[0072] 1. Preparation of Samples
[0073] (1) Fine dust preparation
[0074] Fine dust (PM-10) was dispersed in sterilized distilled water and sonicated for 40 minutes to prevent aggregation. Afterwards, before using the fine dust, it was diluted in serum-free DMEM or MEM medium to a final concentration of 75 μg / mL.
[0075] (2) Preparation of *Byeongpung* root extract
[0076] The roots of *A. tabularis* used in this study were provided by the Gangwon Institute of Natural Environment (Hongcheon, South Korea). Based on preliminary research, extraction conditions were established using the reflux method. After extracting *A. tabularis* roots with 70% ethanol (EtOH), the *A. tabularis* root extract was fractionated according to polarity. Then, solvents were added in the following order to obtain *A. tabularis* root fractions: n-hexane, ethyl acetate (EtOAc), water-saturated (WS)-butanol, and aqueous solution. That is, the 70% EtOH extract was diluted with distilled water, and fractions were sequentially obtained by adding n-hexane, EtOAc, and water-saturated (WS)-butanol in that order. Each fraction was subjected to reduced pressure at 40°C using a rotary evaporator (N-1200A, Eyela, Tokyo, Japan). From the *A. tabularis* root extracts, the ethyl acetate fraction of *A. tabularis* roots was obtained and used in subsequent experiments.
[0077] (3) Preparation of a cosmetic composition containing an extract of *Clematis terniflora*
[0078] The roots of *A. tabularis* used in this study were provided by the Gangwon Institute of Natural Environment (Hongcheon, South Korea). Based on preliminary research, extraction conditions were established using the reflux method. After extracting the roots of *A. tabularis* with 70% ethanol (EtOH), cosmetic compositions containing the *A. tabularis* extract were prepared, and cosmetic compositions containing the *A. tabularis* extract at 0.0005, 0.001, 1, 10, and 12 weight% based on the total weight of the cosmetic compositions were prepared, respectively.
[0079] 2. Experimental Method
[0080] 2.1 Culture and Processing of Artificial Skin
[0081] Three-dimensional (3D) artificial skin models, Neoderm-ED (epidermis + dermis) and Neoderm-ME (epidermis + melanocytes), were purchased from Tego-Science (Seoul, Korea). The artificial skin samples were treated with the fine dust (concentration 75 μg / mL) prepared in 1. for 24 to 72 hours according to experimental conditions, and then cultured at 37°C in 5% CO2. Afterward, the artificial skin samples were fixed in 4% formalin for hematoxylin-eosin (H&E) staining analysis.
[0082] 2.2 Primary Skin Irritation Evaluation Using Neoderm-ED (Epiderm + Dermis) and Neoderm-ME (Epiderm + Melanocyte) Models
[0083] Neoderm-ED and Neoderm-ME, artificial skin samples cultured in Section 2.1, were washed twice with PBS and transferred to 12-well plates containing Neoderm medium for pre-culture at 37°C and 5% CO2 for 24 hours. Subsequently, the artificial skin samples were treated with *Adenophora triphylla* extract (ethyl acetate fraction of *Adenophora triphylla* root) at concentrations of 10, 25, 50, and 75 µg / mL and cultured for another 24 hours. After culture, the samples were treated with MTT solution (500 µg / mL) for 4 hours. Afterward, the medium was removed and DMSO was added, and the absorbance was measured at 540 nm using an ELISA reader (Model 680, Bio-Rad, Hercules, CA, USA). Cell viability of the artificial skin model samples was considered to indicate irritation if it was less than 50%. As a result of treatment with 75 μg / mL of *Calendula ovale* extract (ethyl acetate fraction of *Calendula ovale* root), the cell viability (%) of Neoderm-ED was 79.7% (Fig. 1a) and the cell viability of Neoderm-ME was 77.4% (Fig. 1b), indicating that the *Calendula ovale* extract (ethyl acetate fraction of *Calendula ovale* root) has a low potential for skin irritation and is highly suitable for skin application.
[0084] 2.3 Examples 1 to 4
[0085] Samples treated with the above-mentioned *Clematis terniflora* extract (*Clematis terniflora* root ethyl acetate fraction) at concentrations of 10, 25, 50, and 75 μg / mL were designated as Examples 1 to 4, respectively. The control group represents the state of the three-dimensional (3D) artificial skin models Neoderm-ED (epidermis + dermis) and Neoderm-ME (epidermis + melanocytes) before fine dust treatment. Comparative Example 1 is an artificial skin sample cultured in 2.1, representing the state of the control group after fine dust treatment.
[0086] Fine dust treatment concentration (µg / mL) Bellflower extract concentration (µg / mL) Example 1 75 10 Example 2 75 25 Example 3 75 50 Example 4 75 75 Control group -- Comparative Example 1 (Control group + fine dust) 75 -
[0087]
[0088] Experimental Example 1
[0089] (1) Real-time polymerase chain reaction (RT-PCR)
[0090] Real-time polymerase chain reaction (RT-PCR) was performed to investigate the effects of *Adenophora triphylla* extract (ethyl acetate fraction of *Adenophora triphylla* root) on the mRNA expression levels of skin moisturization-related factors and anti-inflammatory-related factors induced by fine dust. Cells were placed in 6-well plates at 2.5 x 10⁻¹⁰ 5 Cells were seeded at a cell / well density and cultured for 24 hours at 5% CO2. The artificial skin model underwent a pretreatment process. To evaluate the expression of skin-related factors induced by fine dust, the medium was replaced with samples of various concentrations mixed with 75 ppm fine dust and cultured for 24 hours at 5% CO2. mRNA was extracted using the RNA-Spin™ Total RNA Extraction Kit (iNtRON Biotechnology, Gyeonggi-do, Korea), and cDNA was synthesized using PrimeScript™ RT Master Mix (Takara Bio, Shiga, Japan). RT-PCR was performed by mixing 1 μl of cDNA with SYBR Green (Enzynomics, Daejeon, Korea), 1 μl each of forward and reverse primers, and RNase-free distilled water. Real-time PCR was performed using a CronoSTAR™ 96 real-time PCR system (Clontech, Palo Alto, California, USA) under the following conditions: 10 seconds at 95°C, 15 seconds at 60°C, 15 seconds at 72°C, 45 repetitions. GAPDH was used as an internal control. The primer sequences used in RT-PCR and the sequence of GAPDH are shown in [Table 2].
[0091] Primer nameSequencesFilaggrinForward5'-AAGCTTCATGGTGATGCGAC-3'Reverse5'-TCAAGCAGAAGAGGAAGGCA-3'AQP3Forward5'-GGGACCAGTCGGAAGGGAT-3'Reverse5'-CACAGATGGACAGGCTGCCT-3'HAS1Forwar d5'-GTGCGGGTACTGGACGA-3'Reverse5'-GACCGCTGATGCAGGATACA-3HAS2Forward5'-GCAGTGTAAGATATTGGATGGC-3'Reverse5'-CCCATAAATTCTTGATTGTACCAATCTTC-3'iNOSForward5'-CCCTTCGAAGTTTCTG GCAGCAGC-3'Reverse5'-GGCTGTCAGAGCCTCGTGGCTTTGG-3'IL-1βForward5'-TGGACGGACCCCAAAAGATG-3'Reverse5'-AGAAGGTGCTCATGTCCTCA-3'COX-2Forward5'-CACTACATCCTGACCCACTT-3'Reverse5' -ATGCTCCTGCTTGAGTATGT-3'TNF-αForward5'-TTGACCTCAGCGCTGAGTTG-3'Reverse5'-CCTGTAGCCCACGTCGTAGC-3'GPDPHForward5'-CAATGAATACGGCTACAGCAAC-3'Reverse5'-AGGGAGATGCTCAGTGTTGG-3'
[0092]
[0093] All measurements were performed at least three times, and results were expressed as mean ± standard deviation (SD). The statistical significance of the experimental results was determined using the Student t-test with IBM SPSS Statistics 24 software (Armonk, NY, USA). It was considered statistically significant at p < 0.05.
[0094] (2) Experimental results
[0095] 1) Confirmation of inhibitory effect on the expression of inflammatory signaling factors COX-2, iNOS, TNF-α, and IFN-β
[0096] To confirm the anti-inflammatory effect of the extract of Adenophora triphylla (ethyl acetate fraction of Adenophora triphylla root) in skin cells irritated by fine dust, the expression levels of inflammatory signaling factors COX-2, iNOS, TNF-α, and IFN-β were examined (see Figures 2a to 2d). The extract of Adenophora triphylla (ethyl acetate fraction of Adenophora triphylla root) showed inhibitory effects on COX-2, iNOS, TNF-α, and IFN-β even at a low concentration of 10 μg / mL, and significantly inhibited the expression of COX-2, iNOS, TNF-α, and IFN-β as the concentration increased.
[0097] 2) Confirmation of synergistic effect on the expression of filaggrin, AQP-3, HAS-1, and HAS-2, factors involved in skin moisturization and skin barrier strengthening
[0098] To confirm the moisturizing and skin barrier strengthening effects of *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction) on skin cells irritated by fine dust, the expression levels of filaggrin, AQP-3, HAS-1, and HAS-2, which are involved in moisturization and skin barrier strengthening, were examined (see Figs. 3a to 3d). *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction) increased the expression of filaggrin, AQP-3, HAS-1, and HAS-2 even at a low concentration of 10 μg / mL. Filaggrin enhances the formation of natural moisturizing factors (NMF) within the skin and strengthens the skin barrier by reinforcing the stratum corneum. AQP-3 promotes the transport of water and glycerol and improves skin hydration and elasticity. HAS-1 and HAS-2 increase hyaluronic acid.
[0099] (3) Histological analysis using hematoxylin-eosin (H&E) staining
[0100] Histological analysis was performed using a Neoderm-ED artificial skin model composed of the epidermis and dermis to evaluate the restorative effect of *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction) on skin damage induced by fine dust. Through histological analysis using hematoxylin-eosin (H&E) staining, structural changes were observed in the untreated control group, the fine dust-treated comparison group, and the groups treated with fine dust and various concentrations (10, 25, 50, 75 μg / ml) of *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction). While the skin tissue in the control group (Fig. 4(A)) showed a normal structure, the fine dust-treated comparison group (Fig. 4(B)) exhibited epidermal damage, irregularity in stratum corneum formation, and a decrease in dermal tissue density. In the treatment groups of 10, 25, 50, and 75 µg / mL *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction), the skin structure gradually recovered (Figs. 4(C) to (F)), and epidermal thickness and dermal tissue density were significantly improved at concentrations of 50 and 75 µg / mL. These results indicate that the EtOAc fraction effectively alleviates skin damage caused by fine dust and promotes skin barrier recovery. Furthermore, it indicates that it may have preventive and remedial effects on skin inflammation. This suggests that *Scutellaria baicalensis* extract (*Scutellaria baicalensis* root ethyl acetate fraction) is effective as a functional cosmetic ingredient with protective and remedial functions against environmental pollutants.
[0101]
[0102] Experimental Example 2
[0103] Cosmetic compositions according to Examples 5 to 7 and Comparative Examples 2 to 3 were prepared using the extract of *Calendula davurica* prepared in 1. Preparation of Sample (3) above. To confirm the anti-inflammatory effect of the *Calendula davurica* extract in skin cells stimulated by fine dust, the expression levels of inflammatory signaling factors COX-2, iNOS, TNF-α, and IFN-β were checked for cosmetic compositions containing the *Calendula davurica* extract at 0.0005, 0.001, 1, 10, and 12 wt%, respectively. 2. Experimental Methods 2.1 Neoderm-ED (epidermis + dermis) and Neoderm-ME (epidermis + melanocytes) models prepared in the culture and treatment of artificial skin were each treated with the cosmetic compositions. Protein expression levels of COX-2 and iNOS were measured using ELISA, and cytokine secretion levels of TNF-α and IFN-β were analyzed via ELISA (Statistical analysis: results expressed as mean ± standard deviation after 3 replicate experiments, significance tested using Student's t-test (*p< 0.05, **p< 0.01 ***p< 0.001).
[0104] Extract Content (WH%) COX-2 Inhibition Rate (%) iNOS Inhibition Rate (%) TNF-α Production Amount (pg / mL) IFN-β Production Amount (pg / mL) Example 5 0.00 125 ± 4.2 ***30 ± 3.1 ***310 ± 22 ***240 ± 12 ***Example 6 148 ± 5.1 ***55 ± 4.6 ***180 ± 15 ***150 ± 10 ***Example 7 1080 ± 6.0 ***85 ± 5.5 ***60 ± 5 ***50 ± 4 ***Comparative Example 20.00 0512 ± 3.5 ***18 ± 2.7 ***390 ± 18 ***280 ± 15 ***Comparative Example 3 1275 ± 6.8 ***83 ± 6.2 ***70 ± 6***55 ± 5***Control group (untreated with extract) 00 ± 2.10 ± 1.8450 ± 25320 ± 20
[0105] A cosmetic composition containing an extract of *Clematis terniflora* in the range of 0.001 to 10 weight% showed an anti-inflammatory effect depending on the concentration of the extract, and exhibited optimal efficacy at 10 weight% with a COX-2 / iNOS inhibition rate of 80% to 85% and a TNF-α / IFN-β production amount of 50 to 60 pg / mL.
Claims
1. A composition for preventing or improving skin inflammation caused by fine dust, comprising an extract of *Clematis terniflora* as an active ingredient.
2. In Claim 1, A composition for preventing or improving skin inflammation caused by fine dust, wherein the above-mentioned *Clematis terniflora* extract is a *Clematis terniflora* root extract.
3. In Claim 1, A composition for preventing or improving skin inflammation caused by fine dust, wherein the above-mentioned *Clematis terniflora* extract is a *Clematis terniflora* root ethyl acetate fraction obtained by reflux extracting *Clematis terniflora* roots with 70% ethanol (EtOH), diluting the *Clematis terniflora* root extract with distilled water, and then sequentially fractionating it with n-hexane, ethyl acetate, water-saturated butanol, and an aqueous solution.
4. In Claim 1, A composition for preventing or improving skin inflammation caused by fine dust, wherein the above-mentioned *Clematis terniflora* extract inhibits the expression of one or more inflammatory signaling factors selected from the group consisting of COX-2, iNOS, TNF-α, and IFN-β in skin tissue irritated by fine dust.
5. In Claim 3, A composition for preventing or improving skin inflammation caused by fine dust, comprising an ethyl acetate fraction of the root of *Clematis terniflora* at a concentration of 5 to 80 μg / mL.
6. A cosmetic composition for preventing or improving skin inflammation comprising the composition of any one of claims 1 to 5.
7. In Claim 6, The above cosmetic composition is a cosmetic composition for preventing or improving skin inflammation, comprising 0.001 to 10 weight% of a *Clematis terniflora* extract.
8. In Claim 6, The above cosmetic composition is a cosmetic composition for preventing or improving skin inflammation, further comprising water, a surfactant, a moisturizer, or an oil component.
